Summary The effect of hydralazine on tumours appears to vary depending on tumour type. Blood flow and radiation sensitivity decrease more in murine tumours than in human tumour xenografts. In this study a comparison between various tumour types has been made using in vivo 3'P nuclear magnetic resonance spectroscopy (NMRS) to follow the metabolic responses occurring after clamping or intravenous administration of hydralazine (5 mg kg-'). Large increases in the Pi/total phosphate ratio were found with the murine sarcomas, KHT and RIF-1 implanted into C3H/He mice. However little or no effect was seen for the two human xenografted tumours, HX1 18 and HT29 implanted in MFI nu/nu/Ola mice. An 
Summary The effect of hydralazine on tumours appears to vary depending on tumour type. Blood flow and radiation sensitivity decrease more in murine tumours than in human tumour xenografts. In this study a comparison between various tumour types has been made using in vivo 3'P nuclear magnetic resonance spectroscopy (NMRS) to follow the metabolic responses occurring after clamping or intravenous administration of hydralazine (5 mg kg-'). Large increases in the Pi/total phosphate ratio were found with the murine sarcomas, KHT and RIF-1 implanted into C3H/He mice. However little or no effect was seen for the two human xenografted tumours, HX1 18 and HT29 implanted in MFI nu/nu/Ola mice. An intermediate response was observed for KHT tumours grown in nu/nu mice. All tumours showed a large response to clamping. The anaesthetic Hypnorm/Hypnovel has a great influence on the response of the tumour metabolism to hydralazine appearing to both prolong and increase the changes induced. There is evidence to support the theory that the changes in 31p spectra are related to the oxygen status of the tumours.
There is current interest in developing physiological methods for manipulating the oxygen level of tumours (see collected references in 'Chemical Modifiers of Cancer Treatment', ed. Malaise, E.P., Guichard, M. & Siemann, D.W., 1988) . These include systemic treatment with various vaso-active drugs which, by influencing blood flow in tumours, either increase or decrease the level of tumour hypoxia. The drugs nicotinamide and flunarizine both increase radiosensitivity in solid murine tumours, which is indicative of an increase in oxygenation (Horsman et al., 1988; Wood & Hirst, 1988) . Conversely, several studies have shown that high doses of hydralazine (>2.5 mg kg-') induce tumour hypoxia in a variety of experimental tumours (Brown, 1987; Stratford et al., 1987) (Jirtle, 1988) has been reported to occur in transplanted dog tumours (Voorhees & Babbs, 1982) and in various experimental tumours of murine origin (Chaplin, 1988; Horsman et al., 1989; Guichard et al., 1991) .
Preliminary clinical data appear conflicting. An initial study indicates that hydralazine reduces blood flow in tumours of the head and neck region. In contrast, Rowell et al. (1990) has shown that hydralazine increases tumour blood flow in a large series of human lung tumours where changes in blood flow were measured by a radio-tracer technique. These differences may be due to the dose dependent effect of hydralazine: Kalmus et al. (1990) have shown that at low doses (0.5 mg kg-') hydralazine can increase tumour blood flow. Since the evidence for induction of enhanced tumour hypoxia comes almost entirely from studies with transplantable murine tumours, there is a need for studies utilising experimental tumours of human origin.
31P Nuclear magnetic resonance (NMR) spectroscopy has been used to study metabolic changes in murine tumours induced by hydralazine (Okunieff et al., 1988; Dunn et al., 1989; Bhujwalla et al., 1990) . In all these studies an increase in the inorganic phosphate peak (Pi) was observed with a corresponding decrease in the nucleoside triphosphate (NTP) peaks. These changes have been attributed to enhanced anaerobic metabolism arising from increased tumour hypoxia. In one study (Dunn et al., 1989) it was also noted that the spectra changes were greatly affected by the scheduling of the anaesthetic used to sedate the mice during the experiments.
In the present study, 31P NMR spectroscopy has been used to compare the effects of hydralazine in C3H mice bearing murine tumours and mutant immune suppressed nu/nu mice bearing transplanted human xenografted tumours. Murine tumours were also implanted in the nu/nu mice, to determine the effect of mouse host on the tumour response to hydralazine.
Materials and methods

Tumour models
The KHT and RIF-I murine sarcoma lines were maintained as described previously (Twentyman et al., 1980; Stratford et al., 1988) . Approximately 2 x 105 cells in 0.05 ml PBS were implanted subcutaneously into the mid-dorsal pelvic region of 8-12 week old C3H/He mice (category IV). KHT tumours were also implanted into the same region of athymic nude (MFI nu/nu/Ola) mice.
The HX118 human melanotic melanoma line was maintained as described by Cole et al. (1989) and implanted as 0.1 ml aliquots of tumour brei in nu/nu mice. The HT29 human colonic carcinoma was maintained by subcutaneous implants for 1-2 mm tumour pieces into the flanks of the nu/nu mice. For experimental purposes both xenograft tumours were implanted into the mid-dorsal pelvic region. Tumours were used for the NMR studies when they had attained a volume of 300-400 mm3. At least five animals were used per experiment. attributed to the P phosphate of NTP (P-NTP), diphosphodiesters (e.g. uridine-5-diphospho-glucose (UDPG)), nicotinamide adenine dinucleotide phosphate in the oxidised and reduced forms (NADP/NADPH), a and y phosphates of NTP (a-NTP and y-NTP), phosphocreatine (PCr), phosphodiester (e.g. glycerylphosphocholine and glycerylphosphoethanolamine), inorganic phosphates (Pi) and phosphomonoesters (phosphoethanolamine, phosphocholine and some sugar phosphates (PME)). Frequently, a weak line beyond the PME peak was also observed which may be assigned to cyclic phosphates (Brown et al., 1987) . ADP and phosphates of other nucleotides also contributed to the lines assigned to ATP.
Frequency shifts between Pi and PCr (when observable) or NTP peaks were used to estimate pH (Robitaille et al., 1991 In all cases, control spectra were taken before treatment. The mice were then removed from the magnet, treated and returned to the magnet for periods of up to 120 min. Reshimming on the proton signal was carried out each time the coil or the mouse were moved. For the studies beyond 120 min the animals were removed and kept warm for up to 3 h before being returned to the magnet.
Results
Spectral changes induced by clamping Figure 1 shows, for illustrative purposes, the changes in the 31P spectra occurring during clamping for the RIF-1 tumour over a period of 120 min. These changes can be characterised, in all tumours, as an increase in the intensity of the Pi peak, no change in the PME peak and a decrease in the intensity of all other peaks. The PME/Pi ratio is consistently higher in HX118 and HT29 xenografts tumours compared with the murine tumours, RIF-I and KHT. For all tumour types it was found that the peak area ratio Pi/total phosphate was the most consistent method for expressing changes in the phosphorus spectra. This is the ratio of the area of the fitted Pi peak to the total area above the baseline. Figure 2 shows, for all the tumours, the dependence of the ratio Pi/total on the clamping time. With the exception of the HX118 xenograft, all tumours, including KHT in nu/nu mice, showed a maximum value of Pi/total after about 30 min clamping. The rise in the ratio for the melanoma is slower. At the maximum values, Pi/total greater than 0.4, the spectra contain just the two peaks corresponding to Pi and PME (Figure lc) .
The intracellular pH did not change significantly in the KHT, RIF-l or HT29 tumours during clamping. The HXI 18 tumours did exhibit an apparent decline in pH by 40-60 min post clamping (7.03 ± 0.24 to 6.62 ± 0.20, mean ± 1 s.d.). Effect of hydralazine Figure 3 shows the effect of hydralazine administration on the Pi/total ratio in the KHT tumour. The range of values for control and clamped tumours are indicated by the hatched regions in this and subsequent figures. In both anaesthetised and unanaesthetised mice treated with hydralazine, the Pi/total ratios approach those for clamped tumours by about 30 min post-treatment. The ratios in unanaesthetised animals return to control values after about 5 h, whereas in anaesthetised mice, the ratio remains at the value for clamped tumours for at least 24 h, even though the mice have apparently recovered from the anaesthetic at much earlier times. Figure 4 shows that the effect of hydralazine is much less in the RIF-I tumour. In unanaesthetised mice the Pi/total ratios increase significantly but do not reach the levels seen with the KHT tumour. In anaesthetised mice, the effect of hydralazine is both greater and prolonged. However, the ratio at 24 h, although still different from the control, is significantly less than that for clamping. Figure 5 shows that hydralazine does not induce any significant changes in the spectra of the two human xenografts, even when the mice are anaesthetised. The data for the KHT in anaesthetised nu/nu mice ( Figure  6 ) indicate a small rise in Pi/total after hydralazine administration, however this ratio does not attain the high value for the same tumour implanted in C3H mice. The control growth rate of the KHT tumour is very similar whether grown in C3H or nu/nu mice, with the times to reach 4 x the initial volume being 3.2 ± 0.4 and 3.6 ± 0.3 days respectively (means ± s.e.). There was no significant change in intracellular pH for any of the tumours after hydralazine.
Discussion
Severe changes in tumour blood flow should affect both the supply of nutrients, including oxygen, and the removal of waste products. An important question is whether the changes in the 31P spectra in treated tumours are directly attributable to the induction of hypoxia or are due rather to the change in cell metabolism following the restriction of nutrients generally.
Clamping reduces blood flow between the tumour and normal tissue to almost zero (Denekamp et al., 1983) . Hydralazine substantially reduces blood flow in several experimental murine tumours including the Lewis lung carcinoma (Chaplin, 1988) , the SCCVII (Guichard et al., 1990) , the KHT (Honness & Bleehen, 1991) and the RIF-I tumours (Horsman et al., 1989) . In all cases the reported blood flow was reduced to less than 25% of control values. Although there is less evidence for the effect of this drug on human tumour xenografts, Guichard et al. (1991) have shown that hydralazine has less effect on the human tumours Nall and HRTl1 grown in nu/nu mice, only reducing blood flow to approximately 70% of the control value. Reduction of tumour blood flow restricts the supply of oxygen to the tumour cells thereby causing increased resistance to x-irradiation. The time-scale over which the 31P spectra change, following physical clamping of the tumour, is significantly longer than the time required for the induction of radiobiological hypoxia. Complete radiobiological hypoxia is seen for the KHT and RIF-l tumours after only 10 min clamping, whereas the maximum changes in Pi/total ratios are not seen until after 30min of clamping. Furthermore, the radiation resistance of the human xenografts tumours, HX 118, as measured by the growth delay assay, is increased when irradiation is carried out during a 10min clamping period (Cole et al., 1989) . In contrast the NMR data show that the maximum values of the Pi/total ratios for the HX1 18 tumour does not occur until 60 min post-clamping. An explanation for this may be that the severity of hypoxia required for the full induction of radiation resistance is insufficient for the full expression of the metabolic changes indicated by the 31P NMR spectra. Also anaerobic glycolysis could augment the ATP supply and delay the observed response. Anaerobic glycolysis is likely to be accompanied by an acidification; this could explain the prolonged time required by the HX1 18 to achieve maximum changes in the spectra after clamping compared to the other tumours.
The only tumour models in this study significantly affected by hydralazine are the KHT and RIF-1 tumours where the Pi/total ratios are significantly higher than the control values 30 min after drug administration. Complete radiobiological hypoxia is also induced within 30 min of hydralazine (Stratford et al., 1988; Dunn et al., 1989) . Okunieff et al. (1988) have reported similar changes in the 31p spectra after intraperitoneal administration of hydralazine for the FSaII tumour implanted in the hind foot dorsum with a similar relationship to the observed radioresistance induced in this tumour. However, they observed the maximum effect 5 mn after hydralazine, which was maintained for 60 min and returned to normal after 90 min. This difference in the timecourse may be due to the different tumour types, the sites of implantation and the different routes of hydralazine administration. Cole et al. (1989) have shown, using the growth delay assay, that although the HX118 human tumour xenograft becomes significantly more radiation resistant after hydralazine administration, this increased resistance is less than that caused by 10 min clamping. This suggests that the effect of hydralazine on this tumour is less than that for the murine tumours. Guichard et al. (1991) have also shown that hydralazine has little effect on the radioresistance of some other human xenografts. There is no effect on metabolism as seen with 31P spectroscopy for either of the human xenografts used in this study.
For KHT tumours grown in nu/nu mice the effect of clamping on the 31P spectra is similar to that for the same tumour grown in C3H mice. However, the effect of mouse host becomes apparent following hydralazine administration where there are much greater changes observed for the KHT tumour implanted in C3H mice. This cannot be explained by differences in the tumour growth rate and should be investigated further. Guichard et al. (1991) also observed a similar phenomenon between SCCVII tumours implanted in the C3H and nu/nu mice.
The presence of the anaesthetic hypnorm/hypnovel can both increase the magnitude and the duration of the changes in 31p spectra. Although the control values do not seem to be affected, Burney and Field have found that hypnorm/hypnovel does cause a reduction in blood pressure (personal communication). Since hydralazine can also reduce blood pressure in experimental mice (Okunieff et al., 1988) large changes in blood pressure within the tumour could result when hydralazine is administered in conjunction with hypnorm/hypnovel.
In conclusion, the effect of hydralazine on tumours is clearly related to tumour type, the animal host and the presence of anaesthetic. Although it is not yet possible to categorically state that the changes in 31P spectra are directly due to the oxygen status of the tumour, it is likely that this is a major factor determining the relative concentrations of phosphorus metabolites in experimental tumours. Previous studies have shown that the mean P02 values of tumours decrease with increasing size, a change which is coincident with decreasing values of the NTP/Pi ratio (Vaupel et al., 1989; Mueller-Klieser et al., 1990) . Evelhoch et al. (1986) also demonstrated a relationship between the distribution of cellular environments with the RIF-I tumour using 02 perfusion measurements and the tumour metabolic state as reflected in the 31P NMR spectra. These observations suggest that clamping greatly reduces the oxygen status of all the tumour types in this study, but any reduction caused by hydralazine is insufficient for detection by 31P spectroscopy except in the RIF-I and KHT murine tumours.
